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http://dx.doi.org/10.1016/j.kjms.201Abstract We compared the enhancement effect between a newly synthesized tissue-specific
contrast agent, [Gd-DOTA-FPbG], and a commercially available agent, [Gd(DOTA)], in
a murine model of liver tumor using a clinical magnetic resonance imaging scanner. The colon
cancer cell lines with and without b-glucuronidase (bG) expression were implanted into the
liver of mice. Self-synthesized gadolinium-based magnetic resonance contrast agent, [Gd(DO-
TA-FPbG)], was administered to measure enhancement on magnetic resonance images using
a commercially available agent, [Gd(DOTA)], as control in a clinical 3.0 tesla (T) magnetic
resonance scanner. In vivo fluorescence imaging and histopathology of the liver were also per-
formed to compare and correlate with the magnetic resonance studies. The in vivo fluores-
cence imaging failed to depict a sufficiently intense signal for liver or liver tumor of mice
without exposure of the liver following an incision on the abdominal wall. The tissue-
specific magnetic resonance agent, [Gd(DOTA-FPbG)], caused significantly stronger enhance-
ment in tumors expressing bG (CT26/mbG-eB7) than in tumors not expressing bG (CT26)
(p < 0.05). In the magnetic resonance imaging studies using control agent [Gd(DOTA)], the
tumors with and without bG expression depicted no significant difference in enhancement
on the T1-weighted images. The [Gd(DOTA-FPbG)] also provided significantly more contrast
uptake in the CT26/mbG-eB7 tumor than in the normal liver parenchyma, whereas thet of Medical Imaging, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung 807,
(G.-C. Liu).
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MRI of mice liver tumors expressing bG 247[Gd(DOTA)] did not. This study confirms that better contrast enhancement can be readily de-
tected in vivo by the use of a tissue-specific magnetic resonance contrast agent to target
tumor cells with specific biomarkers in a clinical magnetic resonance imaging scanner.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Several methods have been used to detect and assess
hepatic tumors in current clinical practice. These include
imaging studies [1,2], titration of tumor markers [3,4], and
histopathology. Imaging methods usually provide a nonin-
vasive in vivo opportunity to detect and to stage tumors. If
a lesion does not have inherited tissue contrast, which can
be detectable on certain imaging modalities, nonspecific
contrast agents are usually needed to contrast the tumor
and surrounding normal tissue. Examples are iodinated
contrast agents for computed tomography, gadolinium-
based agents for magnetic resonance imaging (MRI), or
microbubble agents for ultrasonography. However, from
a molecular point of view, most of these methods are only
able to detect relatively late-staged, large-sized tumors. To
detect and track tumors earlier, researchers are attempting
to develop various types of tissue-specific contrast agents
for different imaging strategies. These contrast agents can
target tumor cells, with the result that the sensitivity and
specificity of tumor detection improves [5e8]. To achieve
this purpose, a significant amount of the contrast agent
should have affinity with tumor cells, and be readily
detected by in vivo imaging methods.
Certain biomarkers on tumor cells have been identified,
and some of these have also been investigated for this
particular purpose. One of these specific receptors on
tumor cells is b-glucuronidase (bG), an enzyme that exists
generally in cell microsomes (endoplasmic reticulum) and
lysosomes [9]. Its concentration is low in the human serum
and the extracellular substance of normal tissue [10].
However, in previous research, high bG expression on cell
membranes of some tumors has been found [11]. Moreover,
bG expression can also affect tumor biology, such as
metastasis and invasiveness of tumors [11].
Molecular imaging studies using bG as a biomarker have
been done. In former research studies, optical images such
as fluorescence or luminescence were used to track
subcutaneous tumors of small animals [12]. These experi-
ments have succeeded in detecting tumors as well as
monitoring the response to tumor treatments [13].
However, due to limited penetration power, optical image
techniques struggle to detect sufficient signals from the
deep tissues and organs of large animals or humans. To
overcome such limitations, many researchers have
attempted to use different imaging technology, such as
positron emission tomography (PET) [14], single-photon
emission computed tomography (SPECT) [5,15,16] or
magnetic resonance imaging (MRI) [17,18]. PET and SPECT
have high sensitivity to detect and locate tumor tissue.
They can also provide quantification of signal change, so
that lesions may be detected and treatment response
monitored. However, use of radioactive agents andrelatively poor spatial resolution are disadvantages of
nuclear medicine. Synthesis of tissue- or receptor-specific
radiopharmaceutical agents is also not widely available in
clinical settings. MRI provides excellent spatial resolution
without use of ionizing radiation, and has already gained
wide clinical application. However, current MRI with use of
nonspecific extracellular contrast agents is still limited in
sensitivity for detection of diseases down to the molecular
level. Improved signal-to-noise ratio of MRI and synthesis of
tissue-specific agents are obviously required.
The diagnosis of hepatic tumors, such as hepatocellular
carcinoma (HCC), remains a challenge to healthcare
systems worldwide, particularly in epidemic areas of
chronic viral hepatitis B and C [19,20]. These malignant
tumors are highly fatal. Patients with liver cirrhosis caused
by chronic infection of hepatitis B virus, or hepatitis C virus,
alcoholism, nonalcoholic steatohepatitis, and aflatoxin
injury are at high risk. Early detection of small HCCs with
imaging provides the best prognosis. However, current
imaging technologies are still not sufficiently sensitive to
detect small HCCs. According to a systemic review,
regardless of tumor size, sensitivity measures for detecting
HCCs with ultrasound, computed tomography (CT), and MRI
are 60%, 68%, and 81%, respectively [21]. Sensitivity is even
lower for HCCs smaller than 2 cm. According to a study
using explanted liver as standard, sensitivity measures for
ultrasound, CT, and MRI are only 21%, 40%, and 47%,
respectively [22]. More sensitive and specific imaging
strategies are undoubtedly highly desirable.
Based on the reasons previously discussed, we used a self-
synthesized MRI contrast agent, ([Gd(DOTA-FPbG)]) (DOTA-
FPbGZ 1-(2-difluoromethyl-4-(1-(4,7,10-triscarboxymethyl
(1,4,7,10-tetraazacyclodecyl))acetamido)phenyl)-b-D-glu-
copyronuronate) [23], to perform an in vivo MRI experiment
in a murine model of liver tumor. This MRI contrast medium
consists of a gadolinium (III) complex and an enzymatic
moiety (2-difluoromethylphenyl-b-D-galactopyranose). It
can depict significant T1 shortening effect when the tumor
has bG expression. The bG enzyme anchored on tumor cell
membrane can hydrolyze the contrast medium and remove
the b-D-galactopyranose. This molecular process on the cell
membrane of the tumor induces contrast enhancement on
the T1-weighted MRI. It may produce significant contrast
effects between tumors with and without bG, and also
between tumors with bG and normal liver tissue.
This study is aimed to provide principal proof of this
tracer design. We implanted the colon cancers of the mice
that were with and without bG expression separately into
different parts of the animal’s liver. Both optical images
and MRI were performed. To verify the effects of tissue-
specific agents that we synthesized, the commercially
available nonspecific macrocyclic gadolinium-based agent,
[Gd(DOTA)], which possesses similar chemical structures,
248 S.-H. Chen et al.was used as control MRI contrast agent. We compared the
results of these imaging scans, and made correlations with
histology to evaluate the ability of these imaging technol-
ogies in the detection of tumors.
Methods
The culture of tumor cells and animal model setup
Animal experiments were performed in accordance with
institute guidelines. The CT26/mbG-eB7 and CT26 murine
colon carcinoma cells were cultured at 37C in an atmo-
sphere of 5% CO2 incubator. They were grown in Dulbecco’s
Minimal Essential medium (DMEM) (Sigma, St. Louis, MO,
USA) that was supplemented with 5% heat-inactivated
bovine calf serum, 100 U/mL penicillin, 100 mg/mL strep-
tomycin, and 2 mM/L glutamine. The culture medium was
replaced twice a week. After the cells had grown to occupy
approximately 70% of the Petri dish, the cells were
collected and stained with trypan blue. The active cells
must account for more than 90% of total cells. The
concentration of tumor cells was adjusted to 107/mL. Six-
to 8-week-old BALB/c mice, each weighing approximately
25e30 g, were purchased from the National Laboratory
Animal Center, Taipei, Taiwan. 2  106 CT26/mbG-eB7 and
2  106 CT26 tumor cells were injected into the subcuta-
neous tissue of the right and left hind limb, respectively.
Two to 3 weeks after the injection, the tumors had grown to
a diameter of 10e15 mm, then they were removed surgi-
cally and implanted into additional BALB/c mice livers. The
BALB/c mice were injected with 90 mg ketamine and 10 mg
xylazine per kilogram of body weight into the peritoneal
cavity for anesthesia. A 2-cm wound was made on the mice
by a midline incision. The CT26/mbG-eB7 and CT26 tumors,
each an approximately 1e2 mm diameter clump, were
implanted in the right side and left side of the left lateral
lobe liver of the BALB/c mice, respectively, and the muscle
layers and skin were then sutured. After 7 days, the tumor
growth extent of each mouse was confirmed by MRI.
In vivo fluorescence imaging of liver with
CT26/mbG-eB7 and CT26 tumors
After 10e14 days of tumor implantation, the tumors in the
liver had grown up to 5e10mm in diameter. Eachwhole body
image was obtained by performing a 10-second scan using
the IVIS 50 optical imaging system (Caliper Life Sciences,
Hopkinton, MA). Mice were anesthetized using 1% isoflurane,
and then scanned before and after intravenous injection
of fluorescein di-b-D-glucuronide (FDGlcU) (Invitrogen,
Eugene, OR) every 5minutes for 90minutes. Eachmousewas
injected with 500 mg FDGlcU from the tail vein. The images
were taken tomeasure the fluorescence signal intensity, and
the curve of signal was drawn to analyze the signal changes.
In vivo MRI of liver with CT26/mbG-eB7 and CT26
tumors
Twelve BALB/c mice bearing CT26/mbG-eB7 and CT26
tumors 5e10 mm diameter on the right and left side of theleft lateral lobe liver were established. The mice were
anesthetized with 90 mg/kg ketamine and 10 mg/kg xyla-
zine. Each mouse was placed in an animal coil in the prone
position. MRI was performed using a 3T MRI scanner (Sigma;
GE Medical Systems, Milwaukee, WI, USA). T2-weighted
coronal fast-spin echo (FSE) (Repetition time (TR)/Echo
time (TE) 3000/30 ms) and T1-weighted FSE (TR/TE 100/
15 ms) axial images before and after intravenous injection
of the contrast agent ([Gd(DOTA-FPbG)]) were obtained.
After precontrast scanning, six mice were intravenously
injected with 0.1 mmol/kg [Gd(DOTA)-FPbG] from the tail
vein whereas the other six mice were intravenously injec-
ted with 0.1 mmol/kg [Gd(DOTA)] (Dotarem, Guerbet,
France) as a control group. Postcontrast scans were per-
formed every 5 minutes for six subsequent scans. Scans
were captured every 10 minutes until the 90-minute mark
was reached. A glass cylinder of pure water was positioned
adjacent to each mouse as a standard reference. The MRI
signal intensity of liver tissue and both tumors within the
liver were measured, and the curve of signal was drawn to
analyze the signal changes.
Image analysis
The regions of interest from MRI of the tumors, liver tissue,
and the water phantom were selected by the researcher.
The signal intensity of each tumor and liver were normal-
ized to enhancement ratio by dividing their mean target
signal intensity by that of the water phantom (signal to
noise ratio, SI/N). The enhancement percentage of the
targets was calculated as:
Enhancementð%ÞZ ððSI=NÞt  ðSI=NÞpreÞ=ðSI=NÞpre  100
The percentages of SI/N enhancement in different
points in time were compared among different groups.
The results were expressed as the mean  standard
deviation. The statistics were performed with the soft-
ware GraphPad Prism (JMP 8, SAS Institute Inc, Cary, NC;
Prism, GraphPad software Inc, La Jolla, CA, USA). The
two-way analysis of variance using random effect model
was used to compare the difference between groups. Post
hoc comparison for enhancement at each point of time
was also carried out when significant difference occurred.
The p values that were below 0.05 were considered
statistically significant.
Histologic analysis
After the MRI and fluorescent scanning, the tumors and liver
tissues were excised and embedded into a frozen tissue
embedding medium (Tissue-Tek, Sakura Finetek, Torrance,
CA) in a e80C refrigerator. Each tumor and liver tissue
sample was then sectioned into two 10-mm slices. One
section of tissue was stained for bG activity with the bG
reporting gene staining kit (Sigma Diagnostics, St. Louis,
MO) and counterstained with nuclear fast red. Other tissue
sections were stained with a hematoxylin and eosin stain.
Each section was examined using upright BX4 microscopy
(Olympus, Melville, NY).
Figure 1. Time course curve, signal intensity of fluorescent
images of CT26 and CT26/mbG-eB7. The overall signal before
exposing liver is low. The signal intensity of fluorescence does
not demonstrate significant difference between CT26/mbG-
eB7(-) and CT26 tumors(A). After the incision of the
abdominal wall and exposure of the liver, the signal is signifi-
cantly higher than that of the animal without exposure of liver
at 35 minutes after the injection of fluorescent probes
FDGlcU(B).
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In vivo fluorescence imaging of CT26/mbG-eB7 and
CT26 tumors
No significant fluorescence signal was found from the
images of all time periods selected (Fig. 1). During the lastFigure 2. Fluorescent images of CT26 and CT26/mbG-eB7 before
abdominal wall. There was no significant signal from the liver tum
exposure of the liver. The CT26/mbG-eB7 tumor depicts a stronge
excision (right in B). There are some autofluorescent signals exprescan period, we made an incision into the abdomen of
a mouse and exposed the liver tissue for a period of
35 minutes after the injection of fluorescent probes FDGlcU
(Fig. 2A). Then, the image could be detected. There was
a green fluorescence of fluorescein isothiocyanate (FITC) on
the area of the right side of the liver lobe (Fig. 2B). The
results indicated that the FDGlcU probe was actually
hydrolyzed to FITC by bG enzyme in CT26/mbG-eB7 tumor,
but fluorescence of FITC in liver tumors could not be
detected because of the abdominal muscles and skin
barrier.In vivo MRI of liver with CT26/mbG-eB7 and CT26
tumors
As MRI of CT26/mbG-eB7 and the CT26 tumors in liver was
performed, scans were performed on mice to obtain
coronal section images with T2-weighted sequence. The
size and position of tumors could be confirmed from the T2-
weighted image. CT26/mbG-eB7 and CT26 tumors encoun-
tered similar distributions of contrast medium because they
were both implanted in the left lateral lobe of the liver.
The separation distance between tumors was more than
5 mm so that tumors would not fuse together (Fig. 3). The
images of tumors and the liver after the intravenous
injections of contrast medium [Gd(DOTA-FPbG)] showed
stronger signal intensity in the area of the CT26/mbG-eB7
tumor within a period of 5 minutes. The signal enhance-
ment was not present in the area of the CT26 tumor. The
signals of CT26/mbG-eB7 tumors were higher than those of
CT26 tumors 10 minutes after the injection of contrast
agent (Fig. 4), and the appearance of enhancement
remained until it reached 90 minutes. The highest signal in
the average curve of CT26/mbG-eB7 tumors was observed
10 minutes after injection. It showed 25% enhancement
more than the average signal of the CT26 tumors, and 20%
more than an average signal of liver tissues (Fig. 5). The
signals obtained from CT26/mbG-eB7 and CT26 tumors
were significantly different (p < 0.05).(left in A and B) and after (right in A and B) the excision of the
or before the excision. The signals can be detected after the
r fluorescent signal than the CT26 tumor after abdominal wall
ssed on the hairs of the limbs and head.
Figure 3. Photograph of the excised CT26/mbG-eB7 and
CT26 tumors in the left lateral lobe of the liver. No significant
gross difference was seen between these two lesions.
Figure 5. Time-enhancement change of tumors and livers
after intravenous injections of contrast medium [Gd(DOTA-
FPbG)]. The CT26/mbG-eB7 tumor shows a stronger signal
intensity from 5 to 90 minutes. The highest average signal of
the CT26/mbG-eB7 tumor was at 10 minutes. It was about 25%
more enhanced than an average signal of the CT26 tumor, and
20% more than an average signal of liver tissues. The signals
obtained from CT26/mbG-eB7 and CT26 tumors were statisti-
cally different (p < 0.001, N Z 6).
250 S.-H. Chen et al.MRI of CT26/mbG-eB7 and the CT26 tumors in the liver
of the mice was performed with the commercially available
nonspecific MRI contrast agent [Gd(DOTA)]. The apparent
signal enhancement in the liver tissue was observed, but
the signal intensities of CT26/mbG-eB7 and the CT26
tumors were inferior to those of the liver tissues (Fig. 6).
The average signals of CT26/mbG-eB7 and CT26 tumors
showed similar fluctuations along with time (Fig. 7). The
signals obtained from CT26/mbG-eB7 and CT26 tumors
were not significantly different (p > 0.05).Histologic analysis and immune stain of tumors
To confirm the correlation between images and histologic
analysis, BALB/c mice were sacrificed by excessive anes-
thesia, and the liver and tumors after MRI were excised.
These tissues were embedded in the frozen tissue embed-
ding medium and sectored into two 10-mm slices. The slices
were stained with X-GlcA dyes: a bG reporting gene staining
kit, and hematoxylin and eosin stain, respectively. Then,
we compared the MRI scans and tissue sections. As shown inFigure 4. Gd-DOTA-FPbG enhanced T1-weighted MR images
in mice. PreZ Pre-contrast image. The numbers indicate time
(minutes) after intravenous administration of the contrast
medium. The images show higher signal intensity in the CT26/
mbG-eB7 tumor than in the CT26 tumor and liver from 10
minutes after the contrast agent, and the obvious difference
remained constant until 90 minutes. As the time passed, the
signal intensity in livers and CT26 tumors decreased. The signal
intensity in the CT26/mbG-eB7 tumor remains higher than the
other until the end of the scan.Fig. 8, the slice showed CT26/mbG-eB7 tumor and liver
tissues that were stained by hematoxylin and eosin (A and
C), and stained by X-GlcA (B and D). The area of CT26/mbG-
eB7 tumor was dyed with blue color because of the pres-
ence of bG enzyme in the tumor. The CT26 tumor and liver
tissue were not stained blue due to the absence of bG
enzyme in those tissues. The results of histology and MRI
were consistent with the effects of the bG enzyme.
Discussion
In this study, we confirmed that the MRI contrast medium
[Gd(DOTA-FPbG)] could depict tumors with bG expression in
liver of a mouse model. This contrast medium is designed to
target the bG of the tumor cells. The highly expressive bG
enzyme of the tumor cells hydrolyzes the contrast medium
and expresses a T1 shortening effect. At the same time, the
concentration on the tumor cell is also high enough to be
detected by current MRI. In addition, we have also docu-
mented that this imaging strategy can not only detect
tumors, but also differentiate tumors with and without
certain biomarkers in a deep visceral organ in vivo by
a noninvasive imaging modality, i.e., MRI, which has
already been available in most current clinical settings.
In the fluorescence imaging experiment, the in vivo
optical imaging system is unable to detect liver tumorsFigure 6. [(Gd-DOTA)] enhanced T1-weighted MR images in
mice. The numbers indicate time (minutes) after intravenous
administration of contrast medium. Both tumors are relatively
less enhanced than the liver. Pre Z Pre-contrast image.
Figure 7. Time-enhancement curves of the tumors and livers
after intravenous injections of contrast medium [Gd(DOTA)].
The signals of the CT26/mbG-eB7 and the CT26 tumors reveal
no significant difference (p Z 0.67, N Z 6). Both were less
enhanced than the liver.
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imaging of subcutaneous tumor studies. The fluorescence
imaging system is able to detect the size and scope of
a subcutaneous tumor clearly. The signals of the probe in
images are strong and easily detected even in a small
tumor. However, the penetration power of fluorescence is
too weak to penetrate through thick muscle or tissue. This
is why the received signal of the probe from the liver tumor
is not as clear as that from the subcutaneous tumor in the
in vivo optical imaging system. In our experiment, the
signal could be depicted only when the liver tumor was
removed from the abdomen by surgery.
We used the commercially available nonspecific extra-
cellular contrastagent, [Gd(DOTA)], as a control to compare
the enhancement effect with the self-synthesized agent,
[Gd(DOTA-FPbG)]. [Gd(DOTA-FPbG)] and [Gd(DOTA)] bothFigure 8. Histology demonstrates CT26/mbG-eB7 tumor (T Z tu
eosin (A, C), and X- GlcA (B, D). The area of CT26/mbG-eB7 tumor r
reveals no blue stain (D).have the [Gd(DOTA)] chelate with ring structure. The
differencebetween the twocontrastmedia is that [Gd(DOTA-
FPbG)] has the functional structure of glucuronide base to be
hydrolyzedbybGenzymeof the tumor,whereas [Gd(DOTA)]
does not. As the glucuronide base is removed from [Gd(DOTA-
FPbG)], the surplus part of the agent binds with bG or the
albumin and remains in the tumor tissue for a longer time
period. An inference can be confirmed from the time-
enhancement graph in the signal of tumors in the liver with
these two contrast media. Our results showed that the
distribution and the enhancement of extracellular contrast
medium in the liver tissues and CT26/mbG-eB7, and CT26
tumors are not statistically different. This also indicates that
the extracellular space and vascular distribution of CT26/
mbG-eB7 and the CT26 tumors are similar [24]. A different
result for CT26/mbG-eB7 and the CT26 tumor images with
contrast agent [Gd(DOTA-FPbG)] due to perfusion and
extracellular environments is therefore unlikely.
The average signal intensity of liver tissues in the MRI
scan with [Gd(DOTA-FPbG)] and [Gd(DOTA)] is higher than
the signal intensity of CT26 tumors 5 minutes after injec-
tion, and then it decreases rapidly. The fast-increasing and
decaying trend of signal strength of the liver is due to high
blood perfusion in the liver tissues. The contrast media in
the serum are excreted rapidly by the kidney. The liver
tissues remain with just a small amount of contrast media
in extracellular spaces. The signal intensity of liver reduces
quickly and becomes ever closer to the signal intensity of
CT26 tumors.
MRI can be performed successfully in large animals and
humans without limitation of penetration in optical
imaging. It also shows the images with better spatial reso-
lution than those from modalities of nuclear medicine.mor), CT26 tumor and liver tissues stained by hematoxylin and
eveals blue stain (B) because of bG expression. The CT26 tumor
252 S.-H. Chen et al.Therefore, MRI is more clinically transferrable from
preclinical evaluation to real clinical scenarios. There are
other commercial contrast media [18,24,25], e.g., Gd-EOB-
DTPA (Primovist, Bayer, Germany) [26e29], Gd-BOPTA
(MultiHance, Bracco, Italy) [30e32], and ferucarbotran
(Resovist, Bayer, Germany) [32e34], which have certain
affinity to receptors of hepatocyte or Kupffer cell.
However, they do not target tumor cells directly. Just
which agent in which scanning parameters can detect
tumors more accurately than the others is still to be
determined. More studies are required to compare
different imaging strategies for detecting tumors with MRI.
There are limitations to the approach we used in the
study. The bG enzyme does not exist in all membranes
of tumor cells. Some researchers point out that bG was one
of the often-expressed biomarkers on many tumor
membranes. The contrast medium [Gd(DOTA-FPbG)] can be
applied to detect whether the tumor expresses bG enzyme.
Many oncologic studies try to detect special biomarkers and
administer chemotherapy with tumor-specific or sensitive
prodrugs for tumor treatment [35]. These prodrugs may
have a high affinity with tumors and may be activated by
the enzyme in tumor cells. Due to its better tumor affinity,
the dosage and toxicity of patients can be reduced without
compromising the treatment effect. Molecular imaging,
such as our design in this experiment, may also play a role
in management of oncologic patients in the future.
In conclusion, we confirm that better contrast
enhancement can be readily detected in vivo by use of
a tissue-specific MRI contrast agent targeting tumor cells
with specific biomarkers in a clinical MRI scanner. Molecular
imaging strategy can expand to a more clinically feasible
imaging modality as long as tissue-specific contrast agents
can be successfully synthesized and safely administered.Acknowledgments
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